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in an aids patient
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Please refer to the article on page 421 of this issue
to view the questions to which these answers
belong.
C L I N I C A L O U T C O M E
Biopsed tissue from the lesion showed Leishmania
amastigotes (Fig. 1). The Leishmania serology titer
was 1 : 40 (indirect immunofluorescence). Treat-
ment was started with parenteral pentavalent anti-
mony (20 mg of SbV/kg/d) and oral allopurinol
(20 mg/kg/day) for 1 month, with disappearance
of dysphagia in 5 days. Thereafter he was treated
with an intramuscular injection of sodium stibo-
gluconate every 2 weeks. An upper gastrointest-
inal endoscopy 2 months after discharge was
completely normal; histopathology and culture
of biopsy samples were negative for Leishmania.
Eighteen months later he remained asymptomatic,
without evidence of relapse. At that time, the viral
burden was 29000 copies/mL and CD4 lympho-
cyte count 37/mm3.
A N S W E R S
1. Dysphagia, odynophagia, and retrosternal eso-
phageal pain are common occurrences in
patients with advanced HIV infection. The most
common organisms associated with esophagitis
are Candida albicans, cytomegalovirus, and
herpes simplex virus. Rarely, primary lym-
phoma, Kaposi’s sarcoma, histoplasmosis, or
squamous cell carcinoma has been noted in
the esophagus among patients with AIDS [1].
This is a case of esophageal Leishmania in an
AIDS patient without evidence of Leishmania at
any other site. It is thought that approximately
10% of coinfection cases are found in unusual
locations, such as the lungs, larynx and gastro-
intestinal tract [2]. Digestive tract involvement
is common in the course of visceral leishmania-
sis (VL), although it is rarely symptomatic.
Muigai et al [3] found that up to 50% of patients
with VL had enteric Leishmania parasitation.
Furthermore, Laguna et al. [4] isolated Leishma-
nia spp. in 3.2% of gastric or duodenal biopsies
performed in HIV-positive patients with diar-
rhea or upper abdominal pain with negative
stool examination and unresponsive to antifun-
gals. In HIV-infected patients, Leishmania amas-
tigotes have been isolated from rectal, jejunal,
gastric, colonic, and esophageal mucosal biopsy
samples [5]. Stomach and duodenum are the
segments involved in the majority of cases, with
esophageal involvement having been reported
in only a few cases. To our knowledge, only 10
cases of Leishmania esophagitis have been
reported in HIV-infected patients ([6–15];
Table 1).
2. Visceral leishmaniasis is a protozoan infection
with a worldwide distribution that includes the
Mediterranean basin, East Africa, the Middle
East, the Indian subcontinent, and South Amer-
ica. It is estimated that between 25% and 75% of
cases of adult VL occur in HIV-positive
patients; conversely, between 2 and 9% of all
AIDS patients in Southern Europe will develop
VL [2]. In general, the signs and symptoms of
HIV-related VL cases are similar to those
observed in immunocompetent patients, and
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Figure 1 Esophageal biopsy specimen showing macro-
phage containing multiple leishmanial amastigotes (hema-
toxylin-eosin stain; original magnification 400).
Table 1 Leishmania esophagitis in HIV-infected patients: symptoms, diagnosis, treatment and outcome.
Case no.
[reference]
Age/
sex
CD4 þ cell
count (mm3)
Gastrointestinal
symptoms Fever
Culture/
Serology
Endoscopic
results
Positive
smear Treatment Outcome Relapse
1 [6] 27/M 150 Dysphagia
Diarrhea
No
Epigastric pain
NR/Neg Candidal
esophagitis
E, S, D, BM Antimonial agents Failure Yes
2 [7] 30/M 30 Dysphagia
GI bleeding
Yes NR/Neg Candidal
esophagitis
Esophageal ulcer
E, S Antimonial agents
þ allopurinoli
Clinical
improvement
No
3 [8] 24/M 3 Odynophagia
Dysphagia
Yes Pos/NR Esophageal ulcer E, BM Antimonial agents Clinical
improvement
Yes
4 [9] 30/M NR Dysphagia
Odynophagia
Retrosternal pain
Yes Neg/Neg Esophageal ulcer E, BM Pentamidine Clinical
improvement
No
5 [10] 27/M 152 Dysphagia
Odynophagia
NR ND/ND Esophageal ulcer E, S, D Antimonial agents NR NR
6 [11] 27/M 20 Dysphagia No NR/Neg Esophageal ulcer E, BM
improvement
Antimonial agents Clinical Yes
7 [12] 30/F 86 Epigastric pain Yes NR/ND NR E, S, D, BM Antimonial agents
þ g-interferon
Clinical
improvement
No
8 [13] 32/M 124 Odynophagia No NR/Neg Gastroduodenitis E, S, D, BM Pentamidine Clinical
improvement
Yes
9 [14] 29/M 50 Dysphagia Yes Neg/Neg Pseudopoly poid
lesion
E, BM Antimonial agents
þ allopurinol
Amph B
Clinical
improvement
No
10 [15] NR/NR 10 Epigastric pain Yes Pos/NR NR E, L NR NR NR
11 [PC] 31/M 60 Dysphagia No Neg/Neg Excrescent,
esophageal lesion
E
þ
Antimonial agents Clinical
improvement
No
leishmanial amastigotes seen.
NR, not reported; Neg, negative; Pos, positive; GI, gastrointestinal; ND, not done; E, esophagus; S, stomach; D, duodenum; C, colon; BM, bone marrow; L, lung; Amph B,
amphotericin B; PC, present case.
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include high fever, hepatomegaly, splenome-
galy, lymphadenopathy and constitutional
symptoms. Laboratory data include anemia,
leukopenia, lymphopenia, thrombocytopenia
and hyperglobulinemia. As opposed to immu-
nocompetent patients, HIV-infected patients
show a clear tendency to relapse; this has
prompted the use of secondary prophylaxis
in this population. The CD4-cell count is below
200/mL in most patients.
3. Spleen aspirate staining and culture is the most
sensitive method for Leishmania detection.
However, since it is an invasive and potentially
dangerous maneuver, the use of lymph node or
bone marrow aspirates is preferred. Siddig
et al. [16] and Zijlstra et al. [17] evaluated the
sensitivity obtained with different methods of
diagnosis; they found sensitivities of 95–97% for
spleen aspirates, 77–91% for liver biopsy speci-
mens, 52–70% for bone marrow aspirates, and
52–59% for lymph node aspirates. Bone marrow
aspiration is considered the simplest procedure
and the least dangerous for the patient. The
diagnostic yield of these techniques in coin-
fected patients is similar to that in HIV-negative
persons, although bone marrow aspirates could
have a lower yield in advanced AIDS due to the
presence of hypoplasic bone marrow. More
than 40% of coinfected patients show no detect-
able levels of anti-Leishmania antibodies [2].
Although more sensitive techniques have
recently been applied to the serological diag-
nosis of VL in patients coinfected with HIV (e.g.
ELISA, Western blotting), it is clear that a per-
centage of patients cannot develop a humoral
immune response to the parasite. Recently, the
polymerase chain reaction has been applied to
the diagnosis of VL, with promising results [14].
4. In immunocompetent patients, VL usually
responds well to treatment. However, therapy
in HIV-positive patients has not been well
established. Pentavalent antimonial agents
(20 mg/kg/day up to a maximum of 850 mg/
day) have been the mainstay of therapy for
leishmaniasis, but primary unresponsiveness
has been reported in AIDS patients and other
therapeutic modalities should be considered
(i.e. amphotericin B). Moreover, most patients
will relapse unless maintenance therapy is
initiated. One possible approach would be to
use higher initial doses than those recom-
mended (with no upper-limit daily dose) or
to add a second drug, such as allopurinol,
aminosidine, or interferon-g [18]. Alternative
therapy includes liposomal amphotericin B,
pentamidine and azole compounds. Recently,
miltefosine has been shown to be an effective
and safe treatment for VL, with the advantage
that it can be administered orally [19].
D I S C U S S I O N
VL/HIV coinfection presents special problems.
Diagnostic techniques, such as serology, fre-
quently fail. Treatment of VL with conventional
drugs gives poor results with HIV patients.
Furthermore, atypical manifestations are des-
cribed in up to 10% of HIV-positive patients. It
has been suggested that the clinical manifestations
of VL may be influenced by the immunological
status, with atypical locations of Leishmania amas-
tigotes more frequently found in severely immu-
nocompromised patients. Rosenthal et al. [15]
found that patients with a CD4 count of < 50
cells/mm3 had a lower frequency of the clinical
triad of fever, splenomegaly, and hepatomegaly
and, conversely, had a higher frequency of atypical
locations. Accordingly with this, as shown in
Table 1, patients with esophageal leishmaniasis
had advanced AIDS with a mean CD4 count of
68 cell/mm3. This supports the theory that the
response of the immune system plays a role in
the expression of the disease.
Gastrointestinal involvement is relatively com-
mon in HIV-negative patients [3], as well as in
HIV-positive patients [4]. Leishmania spp. can
invade any part of the digestive tract asymptoma-
tically. However, as stressed by Rosenthal et al.
[15], parasitization should be considered when-
ever digestive symptoms are present. Clinical eso-
phageal involvement is very uncommon in HIV-
negative patients, which might be due to the rela-
tively preserved immunity of such patients.
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